Por: Forbes Business March 22, 2023
Aerial view of the 400,000 square foot manufacturing and R&D center BeiGene is building in Hopewell, ... [+] NJ. Business Wire BeiGene, a global biotech company with offices in China, Switzerland and Cambridge, Mass., expects to finish construction of a $700 million investment site in Hopewell, New Jersey next year, on Tuesday. BeiGene had targeted a mid-2023 completion for what it calls the “Princeton West Innovation Campus” when the... + full article
WPLG Local 10 USA Politics April 18, 2023
WASHINGTON – The says New Jersey can withdraw from a commission created decades ago with New York to combat the mob’s influence at their joint port.The high court Tuesday that the Garden State doesn’t need New York’s consent to withdraw from the Waterfront Commission of... + más
Supreme Court: New Jersey can quit mob-busting port agency | Associated Press
This Christmas, your gifts are more likely to have come through New York, now the nation’s busiest shipping port | MarketWatch
Forbes USA Business March 01, 2023
Updated Mar 1, 2023, 02:37pm ESTTopline Shares of the largest Chinese heavyweights trading in the United States surged Wednesday after data showed China's manufacturing sector unexpectedly expanded at the fastest pace in more than a decade last month—adding more than $25... + más
NFL Playoff Scenarios | ABC News
China e-commerce giant Alibaba outlines future strategy | ABC News
MarketWatch USA Business January 22, 2023
A few weeks later, in December, the biotechnology company BeiGene stole the show at the American Society of Hematology’s big annual meeting in New Orleans. BeiGene showing its Btk inhibitor pill, Brukinsa, beating Imbruvica on efficacy and safety in a trial of CLL patients. ... + más
Shaikin: Baseball embracing the 'flukes' and plenty of added revenue this postseason | Los Angeles Times
Watch the wreck of the Brookhill ferry return to the waters of the Mississippi River | The Advocate
The Boston Globe USA Nation December 29, 2022
A new coronavirus variant dubbed XBB has swiftly spreading in the Northeast, jumping from about 35 percent of cases during the week ending Dec. 17 to just over half of cases last week, according to .Here’s a quick primer on what we know about the variant.It is more... + más
Highly Immune Evasive Omicron XBB.1.5 Variant Is Quickly Becoming Dominant in U.S. as It Doubles Weekly | NBC 6 South Florida
Highly immune evasive omicron XBB.1.5 variant is quickly becoming dominant in U.S. as it doubles weekly | CNBC
Business Insider USA Business November 09, 2022
Goldman Sachs promoted 80 people to partner status on Wednesday, marking the largest class since David Solomon took over as CEO in 2018.Twenty-three of the new members are women and seven identify as black — the highest ever figures in both cases, the company said. Nineteen... + más
Goldman Sachs insiders say they are concerned about CEO David Solomon's push to build his personal brand, pointing to staff help for his DJing and use of the firm's planes | Business Insider
Who's up and who's down in the latest Goldman Sachs restructuring under CEO David Solomon | Business Insider
Associated Press USA Sports October 22, 2022
AUCKLAND, New Zealand (AP) — All Times TBA=FIRST ROUND=GROUP A=†New Zealand†Norway†Philippines†SwitzerlandThursday, July 20=At Auckland, New Zealand=New Zealand vs. NorwayFriday, July 21=At Dunedin, New Zealand=Philippines vs. SwitzerlandTuesday, July 25=At Wellington,... + más
FIFA slams unacceptable TV deal offers for Women’s World Cup | The Boston Globe
Column: Even a one-sided Presidents Cup can be entertaining | WPLG Local 10
Forbes USA Life October 14, 2022
Bad Luck: With New York City allowing licenses for up to three casinos, Atlantic City’s monopoly on them in New Jersey could end. Getty If Manhattan builds a casino, the Garden State would lose millions in tax revenue. Now local real estate developers and racetrack... + más
Execs: US internet casino gambling is poised for expansion | Associated Press
As streamers threaten boycott, Twitch takes action on some gambling content | Ars Technica
About iurex | Privacy Policy | Disclaimer |